The FDA approved Lampit (nifurtimox) for the treatment of Chagas disease in children.

Chagas disease, also known as South American trypanosomiasis, is a parasitic disease of tropical diseases.
pathogen is queer trypanosomiasis, which is usually transmitted by trypanosomiasis, commonly known as the kissing worm.
of an infection changes with the progress of the disease.
the early stages of infection, the following symptoms are described as severe: fever, swollen lymph nodes, headache, or local swelling of the location of the bite.
8 to 12 weeks after a bite, the disease enters a chronic period and 60 to 70 percent no longer experiences new symptoms.
30 to 40 percent of people, more symptoms occur 10 to 30 years after the initial infection.
symptoms include enlargement of the heart, 20 to 30 percent of which can even lead to heart failure.
300,000 people are infected in the United States.
an estimated 7 to 8 million people are infected with Chagas disease, mostly in Mexico, Central and South America.
2006, the disease killed about 12,500 people.
Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has approved Lampit ® (nifurtimox) for the treatment of childhood Chagas disease.
Lampit is an antigenic animal drug that, according to prescription instructions, can be specially prescribed to disperse in water and can help pediatric patients who may have difficulty swallowing whole or half tablets.
the adaptation was approved in the context of accelerated approval. Dr Aleksandra Vlajnic, Senior Vice President and Head of Medical Affairs, Bayer Americas,
, said: "Chagas disease can occur at any age and early detection and treatment is important, so treatment in childhood is particularly important in reducing the risk of Chagas disease."
.